ADGRE2 and acute myeloid leukemia: Using flow cytometry to analyse the expression of the 24 candidates in AML specimens, they managed to detect nine targets that are detected in >75% of the cells (expression range: 78–99%, mean 82%): CD82, TNFRSF1B (also known as CD120b), ADGRE2 (also known as EMR2 or CD312), ITGB5, CCR1 (also known as CD191), CD96, PTPRJ (also known as CD148), CD70, and LILRB2 (also known as CD85d).